Alpha Cognition Inc
ACOG
Rangering i aksjer
#20278
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aksjekurs
$8.32
Markedsverdi
$129.22M
Endring (1 dag)
1.59%
Endring (1 år)
65.41%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategori
Healthcare
EPS for Alpha Cognition Inc (ACOG)
EPS per June 2026 TTM: $-0.40
Ifølge de siste økonomiske rapportene og aksjekursen til Alpha Cognition Inc er selskapets nåværende EPS (TTM) $-0.40. Ved slutten av 2022 hadde selskapet en EPS på $-0.18, en nedgang sammenlignet med EPS-en i 2021 som var $-0.37.
EPS-historikk for Alpha Cognition Inc fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
